Background
GlaxoSmithKline owned a portfolio of patents related to clavulanic acid and its potassium salt — a key ingredient in the blockbuster antibiotic Augmentin®. Augmentin combines amoxicillin with potassium clavulanate, where the clavulanate component inhibits bacterial beta-lactamase enzymes, preventing the bacteria from neutralizing the antibiotic. All of the disputed patents traced their lineage to a single parent patent application filed in 1975.
Over the years, the Patent Office required GlaxoSmithKline’s predecessor to divide the original application into separate groups covering the compound itself and methods of using the compound. Two resulting patent families — one issued in 1985 and another issued in 2000-2001 — created overlapping protection. When generic manufacturers including Geneva Pharmaceuticals, Ranbaxy, and Teva sought FDA approval to market generic Augmentin through ANDA filings, GlaxoSmithKline asserted both patent families. The district court found certain patents invalid for nonstatutory obviousness-type double patenting — the doctrine that prevents a patent holder from extending its monopoly by obtaining a second patent that is not patentably distinct from the first. GlaxoSmithKline appealed.
The Court’s Holding
The Federal Circuit affirmed. The court addressed two key issues: whether GlaxoSmithKline’s method-of-use patents were patentably distinct from its earlier compound patents, and whether 35 U.S.C. § 121’s protection against double patenting challenges applied.
On the central double patenting question, the court held that a method-of-use claim is not patentably distinct from an earlier compound patent when the earlier patent’s specification already discloses the identical use. The earlier compound patent claimed clavulanic acid and potassium clavulanate, and its specification disclosed that these compounds inhibit beta-lactamase — the very use claimed in the later method patents. Because the method of using the compound was already disclosed in the compound patent’s specification, the later method claims simply restated what the earlier patent already taught. Extending patent protection through method claims that do no more than practice a use already disclosed in the compound patent runs afoul of the double patenting doctrine.
On the § 121 restriction argument, the court held that the protection afforded by § 121 — which can shield a later-filed divisional application from double patenting challenges — requires strict compliance with documented restriction requirements. GlaxoSmithKline could not demonstrate that its patent families resulted from a restriction requirement that clearly demarcated between the compound claims and the method claims in the way § 121 demands.
Key Takeaways
- A method-of-use patent claiming the use of a compound is not patentably distinct from an earlier compound patent when the earlier patent’s specification already discloses that same use — the later method claims are invalid for nonstatutory obviousness-type double patenting.
- The doctrine prevents pharmaceutical companies from evergreening their patent portfolios by sequentially obtaining compound patents and then method-of-use patents that cover uses already described in the compound patent’s disclosure.
- 35 U.S.C. § 121’s protection against double patenting challenges requires clearly documented restriction requirements that specifically demarcate between the divided claim groups — vague or ambiguous restriction histories will not provide the § 121 shield.
- Patent prosecutors in the pharmaceutical industry should carefully analyze whether method-of-use claims add a use not disclosed in the earlier compound patent’s specification, or whether the later method claims merely reformulate uses already disclosed.
- Generic drug manufacturers can use double patenting challenges to invalidate later-filed method patents on a compound when the compound’s original patent already taught the relevant therapeutic use.
Why It Matters
Geneva Pharmaceuticals v. GlaxoSmithKline is an important precedent in pharmaceutical patent law on the doctrine of nonstatutory obviousness-type double patenting. The pharmaceutical industry routinely seeks to extend patent protection on blockbuster drugs through follow-on patents — claiming not just the compound but also methods of using it, formulations, dosing regimens, and combinations. Double patenting doctrine limits this strategy by preventing a second patent that is not patentably distinct from the first.
The case is particularly significant for Hatch-Waxman litigation, where generic manufacturers filing ANDA applications frequently rely on invalidity challenges to clear the path to market. By confirming that method-of-use claims cannot extend patent exclusivity when the same use was already disclosed in the compound patent, the Federal Circuit provided generic manufacturers with a powerful tool. Patent practitioners drafting pharmaceutical patent portfolios must ensure that method-of-use patents claim uses not already disclosed in earlier compound patents — otherwise later-filed method patents face vulnerability to double patenting invalidity.